| Revista: | Memorias do Instituto Oswaldo Cruz |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000452420 |
| ISSN: | 0074-0276 |
| Autores: | Ennes Vidal, Vítor1 Santos, André Luis Souza dos2 Branquinha, Marta Helena2 d’Avila Levy, Claudia Masini1 |
| Instituciones: | 1Fundacao Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro. Brasil 2Universidade Federal do Rio de Janeiro, Instituto de Microbiologia "Paulo de Goes", Rio de Janeiro. Brasil |
| Año: | 2022 |
| Volumen: | 117 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, prospectivo |
| Resumen en inglés | The treatment for tropical neglected diseases, such as Chagas disease (CD) and leishmaniasis, is extremely limited to a handful of drugs that suffer from unacceptable toxicity, tough administration routes, like parenteral, and increasing treatment failures due to the parasite resistance. Consequently, there is urgency for the development of new therapeutic options to treat such diseases. Since peptidases from these parasites are responsible for crucial functions in their biology, these molecules have been explored as alternative targets. In this context, a myriad of proteolytic inhibitors has been developed against calcium-dependent cysteine-type peptidases, collectively called calpains, which are implicated in several human pathophysiological diseases. These molecules are highly expanded in the genome of trypanosomatids and they have been reported participating in several parasite biological processes. In the present perspective, we discuss our almost two decades of experience employing the calpain inhibitors as an interesting shortcut to a possible repurpose strategy to treat CD and leishmaniasis |
| Disciplinas: | Medicina |
| Palabras clave: | Parasitología, Farmacología, Enfermedad de Chagas, Leishmaniasis, Inhibidores proteolíticos, Calpaínas |
| Keyword: | Parasitology, Pharmacology, Chagas disease, Leishmaniasis, Proteolytic inhibitors, Calpains |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
